Welcome to LookChem.com Sign In|Join Free

CAS

  • or

876371-18-5

CyclohexanaMine, 4-(4-Morpholinyl)-, cis- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

876371-18-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 876371-18-5 Structure

  • Basic information

    1. Product Name: CyclohexanaMine, 4-(4-Morpholinyl)-, cis-
    2. Synonyms: CyclohexanaMine, 4-(4-Morpholinyl)-, cis-;CIS-4-(4-MORPHOLINYL)-CYCLOHEXANAMINE;USUNCAQFNNEGBQ-AOOOYVTPSA-N;(1s,4s)-4-morpholinocyclohexanamine
    3. CAS NO:876371-18-5
    4. Molecular Formula: C10H20N2O
    5. Molecular Weight: 184.2786
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 876371-18-5.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 275.3°C at 760 mmHg
    3. Flash Point: 120.3°C
    4. Appearance: /
    5. Density: 1.045g/cm3
    6. Vapor Pressure: 0.00513mmHg at 25°C
    7. Refractive Index: 1.512
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. CAS DataBase Reference: CyclohexanaMine, 4-(4-Morpholinyl)-, cis-(CAS DataBase Reference)
    11. NIST Chemistry Reference: CyclohexanaMine, 4-(4-Morpholinyl)-, cis-(876371-18-5)
    12. EPA Substance Registry System: CyclohexanaMine, 4-(4-Morpholinyl)-, cis-(876371-18-5)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 876371-18-5(Hazardous Substances Data)

876371-18-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 876371-18-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,6,3,7 and 1 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 876371-18:
(8*8)+(7*7)+(6*6)+(5*3)+(4*7)+(3*1)+(2*1)+(1*8)=205
205 % 10 = 5
So 876371-18-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H20N2O/c11-9-1-3-10(4-2-9)12-5-7-13-8-6-12/h9-10H,1-8,11H2/t9-,10+

876371-18-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name cis-4-(4-Morpholinyl)cyclohexanamine

1.2 Other means of identification

Product number -
Other names Cyclohexanol,4-methoxy-,acetate,cis

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:876371-18-5 SDS

876371-18-5Downstream Products

876371-18-5Relevant articles and documents

COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION

-

Page/Page column 70, (2008/06/13)

The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

-

Page/Page column 70, (2008/06/13)

The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 876371-18-5